PhD Scientific Days 2024

Poster Session L - Health Sciences 1.

Placenta-specific galectin-14 is a potential biomarker for miscarriages

Előadó neve

Farkas, Emese

Neptun code

PCV7V5

Előadó munkahelye

Systems Biology of Reproduction Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences

Előadó telefonszáma

06704090034

Előadó e-mail címe

farkas.emese.vivien@ttk.hu

Az előadás címe

Placenta-specific galectin-14 is a potential biomarker for miscarriages

Szerző(k) neve és munkahelye

Emese Farkas¹, Orsolya Oravecz^2,3, Máté Posta^1,2, Andrea Balogh², Éva Pállinger⁴, Gábor Seregélyes⁴, Nándor Gábor Than^2,5,6

1: Doctoral College of Semmelweis University
2: Systems Biology of Reproduction Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences
3: Doctoral School of Biology, Institute of Biology, ELTE Eötvös Loránd University
4: Department of Genetics, Cell- and Immunobiology, Semmelweis University
5: Department of Obstetrics and Gynecology, Semmelweis University
6: Maternity Private Clinic of Obstetrics and Gynecology

Bemutatás módja

Poszter

Szekció

Poster Session L - Health Sciences 1.

Language of the presentation

Hungarian

Preferred session

Health Sciences

Összefoglaló szövege

In eutherian pregnancies, tightly regulated immune tolerance mechanisms are required at the feto-maternal interface to enable the development of the semi-allogeneic fetus. Several molecules expressed by trophoblast populations act on maternal leukocytes and are involved in this immune adaptation. One example is galectin-14 (gal-14), which is a primate-specific member of the galectin family and predominantly expressed by the syncytiotrophoblast (the outermost layer of fetal membranes) from where it's secreted through nonconventional secretion routes (e.g., via extracellular vesicles, EVs). Several studies indicate that gal-14, along with other galectins, plays a significant role in regulating immune responses at the feto-maternal interface. Dysregulated expression of gal-14 has been associated with pregnancy complications (e.g., preeclampsia).
We investigated whether placental expression of gal-14 and its EV-associated level in the maternal circulation change in spontaneous miscarriages using a previously produced recombinant monoclonal antibody.
The applicability of the gal-14-specific antibody in flow cytometry (FCM) was tested in BeWo cells. These cells were treated with 5-azacytidine (AZA) and/or forskolin (FSK), or vehicle (dimethyl sulfoxid, DMSO) for 96h, and then gal-14 expression was analyzed by qRT-PCR and FCM. Gal-14 levels in maternal plasma EVs of control and miscarriage samples were measured by FCM.
We found that AZA- and/or FSK treatment increased gal-14 expression in BeWo cells both at RNA and protein levels. Interestingly, while we found lower gal-14 expression in the placenta in miscarriages compared to controls, the percentage of circulating gal-14+ middle-size EVs was higher in the first group.
Our results suggest that gal-14 is a biomarker candidate for miscarriages. The decreased placental expression of gal-14 accompanied by its increased levels in the maternal circulation proposes a similar mechanism found for gal-13 in preeclampsia. In the future, larger retro- and prospective studies are warranted to reveal the value of circulating gal-14 in the diagnosis or prediction of miscarriages.
This research was funded by the MTA (LP2014-7/2014 and Premium_2019-436 grants) and by NKFIH (OTKA K128262 and FIEK_16-1-2016-0005 grants).

University

Semmelweis University

Supervisor

Nándor Gábor Than

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

8086

Start

16:20

End

16:23